Remicade Pediatric Indication Likely Faces Safety Scrutiny At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Risks of cancer and fungal infections are likely to grab a great deal of attention from the Gastrointestinal Drugs Advisory Committee when it reviews Centocor Ortho Biotech's Remicade (infliximab) for children July 21.